presentation on vaccines

Got any suggestions?

We want to hear from you! Send us a message and help improve Slidesgo

Top searches

Trending searches

welcome back

85 templates

178 templates

meet the teacher

31 templates

earth science

84 templates

730 templates

112 templates

Vaccine Presentation templates

Against certain illnesses, vaccines are the best—and, sometimes, only—solution. these google slides and powerpoint templates will help you talk about them, providing useful information and powering up your medical slideshows..

• Calendar & Weather
• Infographics
• Marketing Plan
• Project Proposal
• Social Media
• Thesis Defense
• Black & White
• Craft & Notebook
• Floral & Plants
• Illustration
• Interactive & Animated
• Professional
• Instagram Post
• Instagram Stories

It seems that you like this template!

Register for free and start downloading now

Vaccine research.

To combat certain diseases, vaccines are one of the most effective (and sometimes, durable) solutions. Here's a new template where you can give a speech on vaccine research. To surprise your audience, we've opted for an abstract design, but don't worry: there are also photos and some blue tones, which...

COVID-19 Vaccine Breakthrough

Aren't you tired of COVID-19? Great news: vaccines are already here! Use this new editable template to tell your audience all the latest discoveries on the matter. Since blue is the color of safety, we've used it to set the right atmosphere. We've used other resources, such as illustrations of...

The Vaccination Process in Each Country

Finally, vaccines against COVID-19 have been developed and being administered to the general population. But how is each country faring regarding this topic? It's a good time to create a presentation on the matter, and this template will help you save a lot of time. Simplicity in each layout is...

Vaccination Thesis Defense

Vaccines are one of the most important medical developments of the past centuries, they have allowed us to grow as a healthy society and have saved the lives of many people. If your thesis is focused on vaccines, then this template is the perfect one for you. It has lots...

Vaccine Side Effects

As with every medicament and treatment, vaccines also might have side effects, but their benefitial aspects outweigh them by far. This template is ideal for creating presentations about this topic, and now it's a great time to do so due to the COVID-19 vaccination campaign. We've used some creative layouts...

Premium template

Unlock this template and gain unlimited access

The Omicron Variant Medical Infographics

Download the The Omicron Variant Medical Infographics template for PowerPoint or Google Slides and discover the power of infographics. An infographic resource gives you the ability to showcase your content in a more visual way, which will make it easier for your audience to understand your topic. Slidesgo infographics like...

COVID-19 Vaccine Information Breakthrough Brochure

Thanks to vaccines now we can live relatively normal lives without having to worry about covid, they have reduced the symptoms of this infection and have prevented lots of people from dying. However, there are still lots of people who don’t trust these scientifically proven medical tools, so what can...

Celebrating our 2nd Dose! Minitheme

It seemed that the time for vaccination would never come, and the pandemic situation would never begin to calm down, but it has finally arrived! All adults are now almost all vaccinated or about to receive their second dose. This dose is cause for celebration, as we are now fully...

Vaccinations Thesis Statement

There is a lot of information about vaccines and, sadly also a lot of misinformation. It is in health worker’s hands to select only proven information and share it in a clear, understandable way that makes people who don’t understand the subject feel safer and more open to get their...

Cholera Vaccines Breakthrough

Download the "Cholera Vaccines Breakthrough" presentation for PowerPoint or Google Slides. Treating diseases involves a lot of prior research and clinical trials. But whenever there’s a new discovery, a revolutionary finding that opens the door to new treatments, vaccines or ways to prevent illnesses, it’s great news. Should there be...

Time to Vaccinate!

Vaccines help us fight illnesses and save lifes. That’s why it is so important to keep track of all the doses and the vaccinations you need! Vaccination records or cards don’t have to be a boring medical paper, they can look like this creative presentation full of illustrations and stickers....

All About Covid Vaccines Medical Theme

Covid vaccines have dominated the news for several months, which means this template is the height of trendiness! Syringes, viruses, test tubes… it’s all here, with illustrations that complement the data being presented in the form of text, graphs, charts and more. Whether you’re discussing virus variants, vaccination rates or...

Vaccine Immunity Breakthrough

Download the Vaccine Immunity Breakthrough presentation for PowerPoint or Google Slides.Treating diseases involves a lot of prior research and clinical trials. But whenever there’s a new discovery, a revolutionary finding that opens the door to new treatments, vaccines or ways to prevent illnesses, it’s great news. Should there be a...

Rotavirus Vaccination Case Report

Download the Rotavirus Vaccination Case Report presentation for PowerPoint or Google Slides. A clinical case is more than just a set of symptoms and a diagnosis. It is a unique story of a patient, their experiences, and their journey towards healing. Each case is an opportunity for healthcare professionals to...

Pancreatic Cancer Vaccine Breakthrough

Pancreatic cancer arises when cells in the pancreas begin to multiply out of control and form a mass. It’s one of the most common causes of death from tumors. There’s usually late diagnosis since no symptoms are seen in the disease’s early stages and symptoms that might suggest the disease...

Meningitis Vaccine Breakthrough

Download the "Meningitis Vaccine Breakthrough" presentation for PowerPoint or Google Slides. Now you can also edit it online for free! Treating diseases involve a lot of prior research and clinical trials. But whenever there’s a new discovery, a revolutionary finding that opens the door to new treatments, vaccines or ways...

Dark Times Multi-Medical

Due to the COVID-19 pandemic, many people think that we're currently living not-so-good times. Don't let it get to you! This new template is for medical presentations in which you need to explain data about diseases and their impact on population. Despite its name, we've tried a professional approach, with...

Vaccination Infographics

Since vaccines are very important to prevent some dangerous diseases, every single bit of information about them is essential. The amount of infographic designs that are included in this template is astonishing! Some come with an illustration of a vial, others take the form of a record card, and others...

• Page 1 of 3

Jagannath Chatterjee

The eternal problem....

Childhood Illnesses – Road to Health

• Standard childhood illnesses, such as measles, mumps, and even whooping cough, may be of key benefit to a child's developing immune system and it may be inadvisable to suppress these illnesses with immunisations. – Dr Phillip Incao, MD
• Childhood illnesses are a standard feature of childhood because the young body needs them. - Rudolf Steiner, Austrian Scientist
• All acute inflammatory childhood illness--measles, mumps, rubella, chicken pox, scarlatina, or whooping cough--develops the cell-mediated immune system – the deeper immunity
• Childhood illnesses create immunity for life. Vaccines can push diseases to an age where it is dangerous.

Childhood Illnesses Can Prevent Serious Conditions Later in Life

• In early 1997, a team of British physicians writing in Science noted : "Childhood infections may, therefore,�paradoxically protect against asthma.“ These infections�have a purpose in building general immunity.
• Danish physician Tove Ronne in The Lancet in 1985:�"Measles virus infection in childhood can prevent disease in adult life." Among these, Dr. Ronne listed skin disease, immune dysfunctions, degenerative diseases of bone and cartilage, and certain cancers.
• Measles can cure eczema. Induced measles can cause cancer to reduce (remission). Having measles, mumps, rubella in early childhood can prevent against allergies, eczema, asthma , cardiovascular disease mortality and cancer. Polio virus used for cancer remission
• Association of measles and mumps with cardiovascular disease: The Japan Collaborative Cohort (JACC) study.

Kubota Y, et al. Atherosclerosis. 2015. http://www.ncbi.nlm.nih.gov/m/pubmed/26122188/

Childhood Illnesses Protect Against Cancer

• Albonico et al found that adults are significantly protected against non-breast cancers -- genital, prostate, gastrointestinal, skin, lung, ear-nose-throat, and others -- if they contracted measles (odds ratio, OR = 0.45), rubella (OR = 0.38) or chickenpox (OR = 0.62) earlier in life. [ Med Hypotheses 1998; 51(4): 315-20].
• Montella et al found that contracting measles in childhood reduces the risk of developing lymphatic cancer in adulthood [ Leuk Res 2006; 30(8): 917-22].
• Alexander et al found that infection with measles during childhood is significantly protective -- it cuts the risk in half -- against developing Hodgkin's disease (OR = 0.53) [ Br J Cancer 2000; 82(5): 1117-21].
• Glaser et al also found that lymph cancer is significantly more likely in adults who were not infected with measles, mumps or rubella in childhood [ In J Cancer 2005; 115(4): 599-605].
• Gilham et al found that infants with the least exposure to common infections have the greatest risk of developing childhood leukemia [ BMJ 2005; 330: 1294].
• Urayama et al also found that early exposure to infections is protective against leukemia [ Int J Cancer 2011; 128(7): 1632-43].
• In the world of science, it is quite well known that having infections in early life protects against various cancers in later life

Disease Mortality Declined Before Vaccines Introduced – Australian Data . Data from USA, UK, New Zealand & Canada also reflect the same.

Disease Mortality Decline In US (1900-1980) Due to Better Living Conditions, Sanitation, Medical care – JAMA 1999. Vaccines not mentioned. 30 diseases studied. No widespread vaccinations in that period.

US – Major diseases

USA – Diphtheria, Measles

UK & France

Safety of Vaccines Questioned

• A steep rise in cases of Autism (moderate to very severe and mostly permanent disability in children) after more vaccines introduced in 1990’s raised questions over vaccine safety. Parents could know deterioration in children after receiving vaccine shots.
• Doubts raised over use of mercury in vaccines (Thiomersal) and links to Autism. Mercury contamination had led to similar symptoms in Japan and Iraq.
• It became known that Aluminum, Formalin, Polysorbate 80, Phenol, MSG, Neomycin, Squalene, human and animal matter was contained in vaccines.
• More and more parents started reporting vaccination injury and Autism (a severe disorder) after vaccines.

Vaccine Ingredients – a secret well kept

Vaccines and Autism

• Vehemently denied, yet link impossible to hide
• CDC studies trying to disprove link have run into controversies for hiding the link. Scandals during reign of Julie Gerberding
• Scientists openly discussed vaccine autism link – and more dangers – at Simpsonwood (2000) while trying to hide autism link in CDC studies but minutes of meeting were exposed
• Two CDC studies called Verstraeten studies showed very high vaccine autism link. One study was manipulated to show no link and published. The other showing considerable link still lies unpublished
• Another group of CDC studies called Danish studies came crashing down after its Principal Coordinator Dr Poul Thorsen was figured in most wanted list of US Police for having misappropriated the research funds
• Recently the De-Stefano study of CDC came under a storm as its co-author Dr William Thompson revealed data manipulation to hide huge vaccine autism link (340%). Scientists tried to destroy data in 2002.
• CDC now faces Congress investigation. It’s research division “paralyzed with fear”. Congressman Bill Posey submitted on 29 th July 2015

How do vaccines cause Autism?

• As per original CDC study findings, mercury in vaccines is responsible for causing Autism in children. Studies have now shown that mercury even in trace amounts can be responsible
• Independent researchers have also pointed out the clear causative role played by Aluminum present in vaccines
• As per award winning journalist Janine Roberts, the aluminum in vaccines is in form of nano particles so that vaccine ingredients can permeate each cell of the body. Obviously this has a devastating impact on the body.
• Both mercury and aluminum have the ability to cross both blood brain barrier as well as placenta barrier. Thus vaccines given to pregnant women can kick start autism in the infants
• Researchers have also pointed out that the use of animal and human matter in vaccines can cause severe autoimmune reactions and lead to autism
• Vaccines like DPT, DTaP, MMR, Chicken Pox, Hep-B are implicated. Graphs show increase in autism after these vaccines were introduced

Japan – MMR Vac & Autism

Japan – Autism drops as MMR temporarily suspended 1993

AAP Fellow Quits in Protest....

How are vaccines tested for safety?

• Vaccines are tested by manufacturers or persons or agencies under their control. No other agency usually tests them. Phase I to Phase III. Phase IV after release.
• Vaccines are tested on extremely healthy subjects for a very short time (7 to 14) days or till the time adverse events start appearing
• Often serious adverse events are explained away or not reported
• Vaccines are not tested against any genuine placebo. They are tested against the same vaccine without the antigen or some other equally toxic substance
• In India, the Supreme Court and even Parliament has questioned trials but vaccines continue.
• Official vaccinated vs un-vaccinated study never conducted

Vaccines can NEVER be safe for children!

What tests are needed?

• Tests by independent agencies lacking conflict of interest
• Testing against genuine inert placebo and not another vaccine or toxic substance.
• Multiple vaccines given at one visit; never tested!
• Effects of entire vaccine schedule never studied!
• Long term effects never studied! Never studied for causing cancer, infertility, admitted in literature!
• No official studies of vaccinated vs non vaccinated
• Studies required on three generations of mice. Research shows toxicity carried down across generations through breast milk, sperm, epigenetic change
• What is the impact on the human gene? Has it been already altered by vaccines?

1967 study – Trauma of vaccination

Epigenetic Study - 2013

2008: Genes Activated

Independent Vaccinated Vs Non Vaccinated

UK Data – Vaccine Reactions

Adverse reactions – US Data (published MedAlert)

Adverse effects Encountered (MedAlert)

USA, for the year 2013

HPV Vaccines: Deaths now 232 (June 2015)

HPV Vaccine – Reactions Reported

Baby Ian – Allergic Reaction to Hep-B Vaccine

Mercury in Vaccines – Reduced in Developed Nations

• Thiomersal (mercury compound) used in vaccines since 1930. Never tested by FDA. One human study on 21 meningitis patients (1929); all died in short period, attributed to meningitis.
• "As it turns out, we are injecting our children with 400 times the amount of mercury that FDA or EPA considers safe.” - Robert F. Kennedy, Jr. on vaccine-autism-mercury link, 6/22/05
• In June 22, 2000 FDA formally declared that mercury should be removed from vaccines in USA. However mercury still remains as trace amount. Some vaccines still contain mercury in high amounts
• In India and other developing countries full dose mercury remains in all non live virus vaccines �

Mercury – Neurotoxin & Genotoxin

• Mercury -second most poisonous element (second only to uranium). Brain neurons rapidly and permanently disintegrate in the presence of mercury within 30 minutes of exposure. Mercury is known to change a body’s chromosomes. Used as decontaminant in vaccines. Can cross blood brain and placenta barrier
• “Symptoms of high exposure to this class of mercury based compounds include: long term neurological disorders, liver disorders, injuries to the cardiovascular system and hematopoietic system, deafness and ataxia, death.” As genotoxin, mercury is more dangerous in smaller doses.
• Acute poisoning may cause gastrointestinal irritation and renal failure, coordination problems, tremors, mental disorders among many others. Mercury vapour can cause damage.
• Causes Autism as per CDC unpublished study (Relative Risk – 7.6!)

Rat Study – Thiomersal (Mercury Compound in vaccines)

Folia Neuropathol.  2010;48(4):258-69.

Lasting neuropathological changes in rat brain after intermittent neonatal administration of thimerosal.

Olczak M 1 ,  Duszczyk M ,  Mierzejewski P ,  Wierzba-Bobrowicz T ,  Majewska MD .

Thimerosal, an organomercurial added as a preservative to some vaccines, is a suspected iatrogenic factor, possibly contributing to paediatric neurodevelopmental disorders including autism . We examined the effects of early postnatal administration of thimerosal (four i.m. injections, 12 or 240 μg THIM-Hg/kg, on postnatal days 7, 9, 11 and 15) on brain pathology in Wistar rats. Numerous neuropathological changes were observed in young adult rats which were treated postnatally with thimerosal. They included: ischaemic degeneration of neurons and "dark" neurons in the prefrontal and temporal cortex, the hippocampus and the cerebellum, pathological changes of the blood vessels in the temporal cortex, diminished synaptophysin reaction in the hippocampus, atrophy of astroglia in the hippocampus and cerebellum, and positive caspase-3 reaction in Bergmann astroglia. These findings document neurotoxic effects of thimerosal, at doses equivalent to those used in infant vaccines or higher, in developing rat brain, suggesting likely involvement of this mercurial in neurodevelopmental disorders.

PMID: 21225508 [PubMed - indexed for MEDLINE]

• http://www.ncbi.nlm.nih.gov/pubmed/21225508

“Since excessive accumulation of extracellular glutamate is linked with excitotoxicity, our data imply that neonatal exposure to thimerosal-containing vaccines might induce excitotoxic brain injuries, leading to neurodevelopmental disorders..” – Quoted in subsequent study. (2012) http://www.ncbi.nlm.nih.gov/pubmed/22015977

Thiomersal Bottle – Notice the skull & bones warning

In the USA incidence of autism started to dip as mercury in vaccines were reduced by Order but the flu vaccine with mercury was introduced, and aluminum uptake increased in other vaccines

Aluminum – Cause of brain damage

• Aluminum is a suspected carcinogen. It is a cardiovascular or blood toxicant, neurotoxicant, and respiratory toxicant. It has been implicated as a cause of brain damage, and is a suspected factor in Alzheimer’s Disease, dementia, convulsions, and comas. Aluminum can cross the blood brain barrier .
• It suffers synergistic toxicity with mercury and can increase the toxicity of mercury 100 times. Aluminum and mercury are both present in vaccines.
• In humans, there have been reports of a chronic inflammation syndrome called macrophagic myofascitis (MMF) being induced by alum-based vaccines. Symptoms included myalgias, arthralgias, marked asthenia, muscle weakness, and fever. In cats, this vaccine ingredient causes cancers.�

Aluminum in Vaccines & Autism

Formaldehyde - Carcinogen

• Formaldehyde (Formalin in vaccines) is ranked as one of the most hazardous compounds on ecosystems and human health - Environmental Defense Fund. These findings are for environmental exposure, and therefore, the dangers are much greater for the formaldehyde included in vaccines, since it is injected directly into the blood (should not be). Declared carcinogen-Twelfth Report on Carcinogens (2011).
• Toxic symptoms are more than a hundred. Can cause cancer, asthma, eczema, attention and memory problems, damage to reproductive organs, jaundice, kidney pain, menstrual irregularities, schizophrenia like symptoms, sterility, blood vomiting etc
• Formaldehyde, when present with mercury and aluminum, increases toxicity of mercury 1000 times .

Beats logic..

Package Insert - MMR

Package Insert – Hep B Vaccine

Package Insert – Chicken Pox Vaccine

Some other issues with vaccines

• According to medical texts, infants should not be given anything else except breast milk; not even water. Then how do they allow the extremely toxic vaccine injections? – Dr Suzanne Humphries
• Vaccinated mothers no longer have natural antibodies that they can pass on to children via breast milk. Therefore infants have become more vulnerable creating a vicious cycle
• Vaccines are an industrial product, manufactured for profits. Vaccine markets are created to generate more revenue. Effects on children are overlooked.
• Vaccines are now being mandated in the USA and Australia. This is in gross violation of parental rights and also of the Nuremburg Code and AMA’s own guidelines. The Senators pushing these mandates were exposed,paid by pharma as part of their lobbying
• The CDC of USA which recommends vaccines has a for-profit wing which receives generous funds from vaccine industry. Even WHO depends on industry funding. They cannot be trusted.

Are vaccines effective?

• Vaccines are supposed to produce humoral (blood related antibodies) that theoretically protect us against infections? Is this theory correct?
• It is known that, in many instances, antigen-specific antibody titers do not correlate with protection. In addition, very little is known on parameters of cell-mediated immunity which could be considered as surrogates of protection. (Del Giudice G et al, 2001)
• In a study published in Neurology it was demonstrated that titers (the measurement of the levels of antibodies in the bloodstream) were poor indicators of immunity. (Nathan E Crone et al, 1992)
• A titer test does not and cannot measure immunity, because immunity to specific viruses is reliant not on antibodies, but on memory cells – Expert testimony before European Court of Human Rights, 2006

Vaccine Failures!

• Diseases vaccinations are supposed to prevent regularly occur in fully vaccinated populations.
• A measles outbreak in early 1989 among approximately 4200 vaccinated students at a high school and two intermediate schools in suburban Houston, TX, was investigated to evaluate reasons for vaccine failure. (Pubmed)
• Mumps Outbreaks in Vaccinated Populations: Are Available Mumps Vaccines Effective Enough to Prevent Outbreaks? (Pubmed)
• Disease outbreaks are concentrated in highest-vaccinated population – Council on Foreign Relations Graph
• Whooping cough outbreaks are HIGHER among vaccinated children compared with unvaccinated children- Dr. David Witt, infectious disease specialist at the Kaiser Permanente Medical Center in California.
• In India measles vaccine is failing to prevent measles - Report �

Vaccines increase susceptibility!

• Vaccinated individuals are often made more susceptible to the diseases they are vaccinated against and are more likely to die from it.
• Dr R P Garrow reports in the British Medical Journal, Jan 14, 1928, that a person vaccinated against Small Pox was five times more likely to die of the disease than the unvaccinated.
• He also reported, the vaccination was causing a great surge in cases of Small Pox in areas where it was widely given
• Using RTI data doctors in India reported that children given the Oral Polio Vaccine are 6.26 times more likely to suffer paralysis than the unvaccinated.
• Measles after vaccination is more deadly.

Vaccines Cause Serious Side Effects

• The DaPT vaccine Tripedia has listed Autism and ADHD as a side effect. The DPT vaccine is linked to asthma, provocative polio, hyperactivity and learning disorders in children. A 1948 study by Dr Byers et al linked it to deaths, blindness, deafness, spasticity, convulsions, and other severe neurological disorders.
• The Hepatitis B vaccine has been linked to serious adverse effects including cancer of liver. Combination vaccines have more adverse effects; MMR, DPT, Pentavalent etc
• Vaccines are known to cause- Allergies * Asthma * Attention Deficit Disorder *Autism * Auto-immune Diseases * Blindness * Brain Cell Loss *Cancer * Central Nervous System Damage* Deafness * Developmental Damage *DEATH * Diabetes * Epilepsy * Learning Disabilities * Leukemia * Multiple Sclerosis * Neurological Disease * Organ Disease * Psoriasis * Seizures * Shaken Baby Syndrome * SIDS * Total Paralysis * All Diseases in Internal Medicine
• All vaccines can do harm – Dr Andrew Moulden, MD. Vaccines can never be safe – Dr Suzanne Humphries, MD

200 adverse effects compiled from published research papers � http://www.greenmedinfo.com/blog/200-evidence-based-reasons-not-vaccinate-free-research-pdf-download

Vaccine victims are mocked..

Vaccines being opposed by Dr’s and Medical Scientists in India

• BCG – Tested in 15 year trial in India. 0% effective!
• Hep-B vaccine – Meant for promiscuous adults in developed nations, now given to children in developing countries because they refused
• Oral Polio Vaccine – Known to cause polio; both individual cases and epidemics. Court case filed (CCF).
• Pentavalent vaccine – Very high death rate & hospitalization in all countries introduced. CCF
• HPV vaccine – Trial in India conducted unethically killing 7 (9?) tribal adolescent girls. Supreme Court
• Rota Vaccine – Rota diarrhea can be controlled by ORS. The vaccine has serious adverse effect. Recent Indian vaccine to be launched hiding trial data. CCF

How vaccines ‘eradicate disease’

• Disease rates are inflated 100 to 1000 times before vaccines are introduced
• Disease definition is changed when vaccines are introduced making it difficult to report the disease
• Doctors are advised that, ‘vaccinated children cannot come down with the disease vaccinated against’. So they change disease names when such cases come up
• Symptoms (for the same disease) are bifurcated to create new disease names and show drop in cases
• Pathology samples can be checked in only pre-selected laboratories so that positive cases can be suppressed
• Low level health workers or officials cannot report disease, they have to go through ‘experts’ who can then suppress cases

How Polio Was “Eradicated”

• 32,419 cases of the disease were inflated to 3,50,000. In India the figure was 12,000
• Definition of polio was changed three times to bring down number of cases
• A disease name called “Non Polio Acute Flaccid Paralysis” was created to bifurcate polio figures. Polio is traditionally infantile paralysis. It was changed to viral polio. Earlier 20 days duration was required to identify polio, it was increased to 60 days.
• Pathological tests could be carried out only in select WHO certified laboratories
• Cases of polio caused due the vaccine were suppressed
• Paralysis in children increased from 1005 in 1996 to 60,992 in 2012 after India was declared polio free!

Polio Vac – Controversial since 1955!

Oral Polio Vac and Cancer!

Polio Incidence & Pesticide (DDT)

Change in Polio Definition

• Traditionally infantile paralysis of any kind lasting more than 24 hours was recorded as polio
• After vaccine introduced only polio caused by 3 enteroviruses were considered polio. Other paralysis was given different names
• Later paralysis had to last more than 20 days
• This was increased to 60 days
• In addition, stools had to confirm presence of PV
• Only WHO accredited laboratories can confirm
• Polio caused by vaccine or vaccine strain virus turned virulent cannot be called polio
• Polio recorded as “Non Polio Acute Flaccid Paralysis”
• “Clinically indistinguishable and twice as deadly” –Dr’s

Polio – Controlled by vaccine?

You think Small Pox Was Eradicated by Vaccines?

• The practice of inoculation (against small pox) manifestly tends to spread the contagion, for a contagious disease is produced by innoculation where it would not otherwise have produced. The Gentleman’s Magazine and Historical Chronicle, vol.34, 1764,p.333
• In the 38 years after the start of innoculation, deaths from small pox relative to the number born increased to 127 per 1,000 (a 41 % increase) and relative to the number of burials (deaths) 81 per 1,000 (a 27% increase). The Great Small Pox Epidemic of 1775-82, History Today, July 20, 2003, p.12
• Since the late 1700s, the medical profession has supported vaccination without comparing vaccinated and unvaccinated. MMWR, vol.50, CDC, June 22, 2001, pp1-25
• ...the level of antibody that protects against small pox is unknown. ibid

Why did Gandhi revolt against vaccines?

• Gandhiji revolted against vaccines and declared it a ‘filthy process’. Why?
• “When we recall that vaccine lymph is derived, in the first place, either from a small pox corpse, the ulcerated udder of a cow, or the running sores of a sick horse’s heels...it has far reaching ill effects on the human constitution”. Studies in Vaccinia, The Lancet, vol. 1999, no.5150, May 13, 1922
• No practitioner knows whether the lymph he employs is derived from small pox, rabbit pox, ass-pox or mule pox. Ibid. (What viruses were in the vaccines? Even CDC does not know! Admitted after genetic assay of Dryvax)
• Some of the animals that have been used to passage today’s vaccine virus include rabbits, mice, goats, cows, pigs, horses, sheep, dogs, birds and humans.�

Small Pox Vaccine & Cancer

What else did the vaccine cause?

• “In these cases it is highly likely that acute infectious hepatitis was a result of contamination of human lymph derived vaccine. Other infectious diseases attributed to vaccination includes tuberculosis & syphillis” New York Times, Sept 26, 1869
• In the year 1981, a WHO consultant released to the media, that his investigation into the AIDS epidemic under the instruction of WHO, clearly revealed that HIV spread to humans from primates due to the small pox vaccine. WHO suppressed the report.
• The vaccine was linked to eczema vaccinatum with a fatality rate of 4-40%. Also linked to erisypelus epidemics which had high mortality rates. CNS damage.
• Huge epidemics of small pox in 1872-73 (Boston) started AFTER introduction of vaccine.

Leicester Small Pox Spike After Mandatory Vaccination. This UK state eliminated small pox with isolation, sanitation and nutrition

Testimonial of a Nobel Prize Winner

Blind Belief in Doctors – Not Recommended!

Educate before you vaccinate!

• Neither government or doctors will inform you about vaccine dangers
• If your child dies, becomes disabled or diseased it will be denied by authorities and marked ‘coincidence’
• You will not receive any free treatment, compensation or any rehabilitation help for your child
• The very doctor who vaccinated your child will become your enemy
• Doctors receive commissions, political parties receive funds, bureaucrats receive perks and promotions. You gain a dead, sick or disabled child!
• As per a law signed into effect in the USA in 1986 vaccine manufacturers and even individual vaccines are protected from law suits
• Vaccine industry & doctors protected, not your child!

Profitable industrial product

To Protect Your Child

• Ensure adequate age for marriage
• Provide proper nutrition and care for pregnant mother
• Homeopathic treatment during pregnancy will ensure a healthy child. Search for senior homeopath.
• Avoid drugs and vaccines during pregnancy. The tetanus vaccine being given during pregnancy is also used to sterilize girls and women in developing nations (used in India, Kenya). It can cause abortions and premature birth.
• Go in for natural child birth. Delay cord clamping. Do not clean child immediately after birth. Learn from natural birth movement. Aisharwaya Rai Bachhan did this!
• Give the first yellow milk – colostrum- to your child. You can breastfeed up to 2 years & beyond for benefits and emotional bonding
• Give baby homeopathic treatment during illnesses

What do other systems recommend?

• Ayurveds flay village practice of giving even a drop of honey to infants
• Homeopathic texts talk about giving medicines to mothers so that children get it through breast milk
• Pregnancy, infancy and childhood are to be respected
• General practitioners (GP’s) were wary about medicating these groups. Vaccination was selective based upon child’s health. Many also conducted skin tests before administration. Seniors were more cautious and even skipped them if they perceived no threat
• Things changed after paediatricians arrived on the scene. They are reckless about vaccination and prescribing antibiotics etc for resultant conditions

Role of civil society

• Medicine is too important to be left at the hands of doctors. Civil society should not forget its watchdog role
• Civil society representatives should be a part of the National Technical Advisory Group on Immunizations that advises GoI on vaccinations
• The civil society should sensitize doctors on vaccine dangers. The industry keeps them in the dark
• Awareness about the murky world of vaccines ought to be created among the general populations
• Should demand a vaccine adverse event reporting system with compulsory reporting and monitor the same and seek compensation and rehabilitation for victims
• Vaccines crimes need to be referred to civil and criminal courts. Protecting vaccines is the goal of medical boards.

Be scientific...

Vaccine Information Websites

• www.nvic.org
• www.sanevax.org
• www.mercola.com
• www.greenmedinfo.com
• www.vaccineresearchlibrary.com
• www.vactruth.com
• www.vaccinetruth.org
• www.currenthealthscenario.blogspot.in
• www.vaccinationinformationnetwork.org
• www.naturalnews.com

• Skip to main content
• Skip to FDA Search
• Skip to in this section menu
• Skip to footer links

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

U.S. Food and Drug Administration

•   Search
•   Menu
• Advisory Committees
• Advisory Committee Calendar
• Vaccines and Related Biological Products Advisory Committee October 14-15, 2021 Meeting Announcement - 10/14/2021

Advisory Committee Meeting | Virtual

Event Title Vaccines and Related Biological Products Advisory Committee October 14-15, 2021 Meeting Announcement October 14 - 15, 2021

What is an advisory committee.

Advisory committees provide independent expert advice to the FDA on broad scientific topics or on certain products to help the agency make sound decisions based on the available science. Advisory committees make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so. Please see, " Advisory Committees Give FDA Critical Advice and the Public a Voice ," for more information.

Please note that due to the impact of this COVID-19 pandemic, all meeting participants will be joining this advisory committee meeting via an online teleconferencing platform.

The online web conference meeting will be available at the following: 

• Youtube: https://youtu.be/BhlshZ7Lkr0
• Yorkcast: https://fda.yorkcast.com/webcast/Play/feeef31603f54d6fb06189e7fb3074651d  
• Youtube: https://youtu.be/c-H40GrvWz4
• Yorkcast:  https://fda.yorkcast.com/webcast/Play/619cf18fbc6c4c598c7ee996e029bcf61d

Agenda The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform. Under Topic 1, the committee will meet in open session to discuss the Emergency Use Authorization (EUA) of the ModernaTX Inc. COVID-19 vaccine for the administration of an additional dose, or “booster” dose, following completion of the primary series, to individuals 18 years of age and older. On October 15, 2021, under Topic II, the committee will meet in open session to discuss the Emergency Use Authorization (EUA) of the Janssen Biotech Inc. COVID-19 vaccine for the administration of an additional dose, or “booster” dose, to individuals 18 years of age and older.

Meeting Materials FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its website prior to the meeting, any background material will be made publicly available at the time of the advisory committee meeting, and additional materials will be posted on FDA's website after the meeting.

Materials for this meeting will be available at the Vaccines and Related Biological Products Advisory Committee meetings main page .

The meeting will include slide presentations with audio components to allow the presentation of materials in a manner that most closely resembles an in-person advisory committee meeting.

Public Participation Information Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.

FDA is establishing a docket for public comment on this meeting. The docket number is FDA-2021-N-0965.

The docket will close on October 13, 2021. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before October 13, 2021. The https://www.regulations.gov electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of October 13, 2021. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date.

Comments received on or before October 12, 2021, will be provided to the committee. Comments received after October 12, 2021, and by October 13, 2021, will be taken into consideration by FDA. In the event that the meeting is cancelled, FDA will continue to evaluate any relevant applications, submissions, or information, and consider any comments submitted to the docket, as appropriate.

You may submit comments as follows:

Electronic Submissions

• Federal eRulemaking Portal: https://www.regulations.gov . Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov
• If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).

Written/Paper Submissions

• Mail/Hand delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.”

Instructions: All submissions received must include the Docket No. FDA-2021-N-0965 for “Vaccines and Related Biological Products; Notice of Meeting; Establishment of a Public Docket; Request for Comments.” Received comments, those filed in a timely manner (see ADDRESSES), will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500.

• Confidential Submissions--To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission.  You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” FDA will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov . Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify the information as “confidential.” Any information marked as “confidential” will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA’s posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf .

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500.

FOR FURTHER INFORMATION CONTACT: Prabhakara Atreya or Kathleen Hayes, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 6306, Silver Spring, MD 20993-0002, 240-818-7798, via email at [email protected]; or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area).  A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency’s website at https://www.fda.gov/advisory-committees and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before joining the meeting.

On October 14, 2021, oral presentations from the public will be scheduled between approximately 12:45 p.m. Eastern Time and 1:45 p.m. Eastern Time and approximately between 11 a.m. and 12 noon Eastern Time on October 15, 2021.

Those individuals interested in making formal oral presentations should notify [email protected] and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before 6 p.m. on October 8, 2021.

Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by October 12, 2021.

Webcast Information CBER plans to provide a free of charge a live webcast of the Vaccines and Related Biological Products Advisory Committee meeting. If there are instances where the webcast transmission is not successful, staff will work to re-establish the transmission as soon as possible. 

The online web conference meeting will be available at the following links listed above.

Contact Information

• Prabhakara Atreya or Kathleen Hayes: [email protected]
• FDA Advisory Committee Information Line: 1-800-741-8138 (301-443-0572 in the Washington, DC area) Please call the Information Line for up-to-date information on this meeting.
• For press inquiries, please contact the Office of Media Affairs at [email protected] or 301-796-4540.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our website for procedures on public conduct during advisory committee meetings .

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Official FR Notice

A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency’s website or call the committee’s Designated Federal Officer (see Contact Information) to learn about possible modifications before coming to the meeting.

Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact the committee’s Designated Federal Officer (see Contact Information) at least 7 days in advance of the meeting.

Answers to commonly asked questions including information regarding special accommodations due to a disability may be accessed at: Common Questions and Answers about FDA Advisory Committee Meetings .

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at Public Conduct During FDA Advisory Committee Meetings for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.2).

Event Materials

Pulitzer Center Update August 14, 2024

Applications Open: Fall 2024 Teacher Fellowship, "Making Connections to Global Health Stories"

From climate change to social justice, Pulitzer Center journalism cuts to the core of the world’s biggest challenges by exploring key issues that connect us all. Over the past four years, the over 100 educators who have participated in our  Teacher Fellowship program have extended the impact of Pulitzer Center stories through deep classroom engagement by over 6,500 students  with reporting that deepens their critical understanding of global issues and inspires them to meet global and local challenges with curiosity, empathy, and empowered action. 

This fall, Teacher Fellows will explore the following theme:

Making Connections to Global Health Stories

As part of this paid, virtual Fellowship, a cohort of up to 14 educators will explore global health stories over the course of six workshops in a community with other passionate Fellows, award-winning journalists and the Pulitzer Center education team. They will analyze how news stories engage students in critical analysis of several global health topics, guide students in making local connections, and explore paths for students to apply their learning to address health issues in their own communities. Ultimately, educators will design a rigorous learning experience that centers at least one news story and culminates in an activity exemplifying empowered action. Participants will share the results of this learning experience by publishing a narrative blog post or lesson plan capturing student learning, engagement, and empowered action.

Click here to apply! Applications are due Sunday, September 8, 2024

Upon successful completion of the program, Fellows will be provided with …

• $600 stipend (made in two payments of $300 disbursed in November 2024 and January 2025)
• Pulitzer Center Teacher Fellow digital badge
• Certificate for 30 professional learning units (PLUs)

If you have questions after reading the eligibility requirements and Fellowship details below, please reach out to us at  [email protected] .

The Pulitzer Center is committed to making real, measurable progress on diversity, equity, and inclusion in all of our programs and partnerships. Please review our  Diversity, Equity, and Inclusion statement for more information on our commitments. Educators from historically marginalized backgrounds, and/or educators who are teaching students from historically marginalized backgrounds, are strongly encouraged to apply.

Eligibility Requirements:

This Fellowship is open to all classroom teachers (grades four–12) working in public, charter, independent, and alternative schools in the United States and U.S. territories. Educators working with adults and youth in jails, prisons, or youth detention facilities are also encouraged to apply. Applicants must be currently teaching virtually or in person, and plan to continue teaching in their current school at least through the end of the 2024–2025 school year. 

Because all sessions will be held virtually, applicants must have stable internet access and a computer with a webcam and microphone.

Fellowship Description:

Through text analysis, group discussion, and engagements with journalists, Fellows will practice applying a media literacy lens to global health news stories on a range of topics, including the health impacts of pollution and extreme weather events, vaccine access, maternal health, disparities in health care access, gender equality, and health research and innovation. Fellows will connect with journalists who cover global health topics through a myriad of storytelling methods, including print, video, photography, and data. Participants will strengthen the skills to ask critical questions and make informed connections between local and global issues. They will also evaluate how news stories can inspire broader classroom discussions about health.

Guiding questions:

• How do individual health outcomes reflect the impact of larger systemic issues (i.e. ,climate change, migration, human rights) in communities?
• How do systemic health issues connect  to challenges faced by students and their communities?
• Why is it important to bring discussions about health to our classrooms? How can critical analysis of news stories support those discussions and equip students to take action?

Teachers will design a short learning experience (one-three class periods) that centers at least one global health topic and culminates in an activity exemplifying empowered action. Teachers will be responsible for documenting student learning in a narrative blog or a lesson plan with embedded student examples.

Fellowship Requirements:

Fellows will participate in a virtual orientation on Saturday, October 5, 2024, and join five weekly evening sessions from October 2024 through November 2024. Each evening session will be two hours long and three will feature discussions with experienced journalists covering global health topics. Other sessions will focus on strategies and resources to engage students, lesson brainstorming and development, and opportunities for peer feedback. All sessions will be held live via Zoom.

With the support of the Pulitzer Center education team, all Fellows will …

• Create a lesson plan centering a global health news story from the Pulitzer Center website 
• Facilitate their lesson with students in November 2024
• Document and share their experience by writing a narrative account or sharing a lesson plan that captures students’ instructional journey. The blog post/lesson plan can include teaching materials, evaluation materials, student quotes, and images/videos that capture student engagement. 

Fellows’ work will be shared on the Pulitzer Center website. Fellows may also have the opportunity to participate in professional development webinars and/or conference presentations.

The Fellowship will launch on Saturday, October 5, 2024, and conclude on Wednesday, December 9, 2024. 

While the exact amount of time spent by each Fellow will depend on his or her classes and projects, we anticipate the Fellowship time commitment to be about 30 hours. This includes participation in virtual workshops, project design, implementation, and evaluation.

• Saturday, October 5, 2024, 11:30 am-4:30pm ET
• Wednesday,  October 9, 2024, 6:00-8:00pm ET
• Wednesday, October 16, 2024, 6:00-8:00pm ET
• Wednesday, October 23, 2024, 6:00-8:00pm ET
• Wednesday, October 30, 2024, 6:00-8:00pm ET
• Wednesday, November 6, 2024, 6:00-8:00pm ET
• Implementation of lesson plan:  November 6 -December 6, 2024 
• Closing: Wednesday, December 11, 2024, 6:00-8:00pm ET

Deliverables and Fellowship Payments:

• Week of November 25, 2024:  Process first payment of $300 upon completion of first six workshops
• Monday, December 9, 2024:  Final deliverables due
• Week of December 16, 2024:  Process second payment of $300 upon review of lesson plan or blog post  

If you have additional questions, please contact us by emailing [email protected] . We look forward to hearing from you!

Learn more about past Teacher Fellows and their work  here .

RELATED TOPICS

Health Inequities

Health Science

Water and Sanitation

Outbreaks and Epidemics

RELATED CONTENT

Teacher fellowship.

August 17, 2021

Teacher Fellowship Engages 1,300 Students in Projects Inspired by Global Reporting

August 6, 2024

Advertisement

Supported by

W.H.O. Declares Global Emergency Over New Mpox Outbreak

The epidemic is concentrated in the Democratic Republic of Congo, but the virus has now appeared in a dozen other African countries.

• Share full article

By Apoorva Mandavilli

The rapid spread of mpox, formerly called monkeypox, in African countries constitutes a global health emergency, the World Health Organization declared on Wednesday.

This is the second time in three years that the W.H.O. has designated an mpox epidemic as a global emergency. It previously did so in July 2022. That outbreak went on to affect nearly 100,000 people , primarily gay and bisexual men, in 116 countries, and killed about 200 people.

The threat this time is deadlier. Since the beginning of this year, the Democratic Republic of Congo alone has reported 15,600 mpox cases and 537 deaths. Those most at risk include women and children under 15.

“The detection and rapid spread of a new clade of mpox in eastern D.R.C., its detection in neighboring countries that had not previously reported mpox, and the potential for further spread within Africa and beyond is very worrying,” said Dr. Tedros Adhanom Ghebreyesus, the W.H.O.’s director general.

The outbreak has spread through 13 countries in Africa, including a few that had never reported mpox cases before. On Tuesday, the Africa Centers for Disease Control and Prevention declared a “public health emergency of continental security,” the first time the organization has taken that step since the African Union granted it the power to do so last year.

“It’s in the interests of the countries, of the continent and of the world to get our arms around this and stop transmission as soon as we can,” said Dr. Nicole Lurie, the executive director for preparedness and response at the Coalition for Epidemic Preparedness Innovations, a nonprofit that finances vaccine development.

We are having trouble retrieving the article content.

Please enable JavaScript in your browser settings.

Thank you for your patience while we verify access. If you are in Reader mode please exit and  log into  your Times account, or  subscribe  for all of The Times.

Thank you for your patience while we verify access.

Already a subscriber?  Log in .

Want all of The Times?  Subscribe .

• Today's news
• Reviews and deals
• Climate change
• 2024 election
• Fall allergies
• Health news
• Mental health
• Sexual health
• Family health
• So mini ways
• Unapologetically
• Buying guides

Entertainment

• How to Watch
• My Portfolio
• Latest News
• Stock Market
• Biden Economy
• Stocks: Most Actives
• Stocks: Gainers
• Stocks: Losers
• Trending Tickers
• World Indices
• US Treasury Bonds Rates
• Top Mutual Funds
• Options: Highest Open Interest
• Options: Highest Implied Volatility
• Basic Materials
• Communication Services
• Consumer Cyclical
• Consumer Defensive
• Financial Services
• Industrials
• Real Estate
• Stock Comparison
• Advanced Chart
• Currency Converter
• Credit Cards
• Balance Transfer Cards
• Cash-back Cards
• Rewards Cards
• Travel Cards
• Credit Card Offers
• Best Free Checking
• Student Loans
• Personal Loans
• Car insurance
• Mortgage Refinancing
• Mortgage Calculator
• Morning Brief
• Market Domination
• Market Domination Overtime
• Asking for a Trend
• Opening Bid
• Stocks in Translation
• Lead This Way
• Good Buy or Goodbye?
• Financial Freestyle
• Capitol Gains
• Fantasy football
• Pro Pick 'Em
• College Pick 'Em
• Fantasy baseball
• Fantasy hockey
• Fantasy basketball
• Download the app
• Daily fantasy
• Scores and schedules
• GameChannel
• World Baseball Classic
• Premier League
• CONCACAF League
• Champions League
• Motorsports
• Horse racing
• Newsletters

New on Yahoo

• Privacy Dashboard

Yahoo Finance

Gritstone bio reports second quarter 2024 financial results and provides corporate updates.

-- Preliminary randomized Phase 2 data suggest GRANITE (personalized neoantigen vaccine) could drive meaningful clinical benefit in front-line metastatic microsatellite-stable colorectal cancer (MSS-CRC); mature progression-free survival (PFS) data expected in the third quarter of 2024 --

-- Recent KOL event and patient advocacy engagements underscore the unmet need for new treatment options in metastatic colorectal cancer --

-- Presentations at AACR 2024 and ESCMID Global 2024 demonstrate the broad potential of Gritstone’s oncology and infectious disease vaccines --

-- Cash, cash equivalents, marketable securities and restricted cash of $61.7 million as of June 30, 2024 --

EMERYVILLE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today reported financial results for the second quarter ended June 30, 2024 and provided recent corporate and clinical updates.

“This is an exciting time for Gritstone, as we are on the cusp of unlocking important data about our promising new therapeutic modality in front-line metastatic microsatellite-stable colorectal cancer (MSS-CRC),” said Andrew Allen, MD, PhD, Co-founder, President & CEO of Gritstone bio. “Up to 95% of patients with metastatic CRC, the second most common cause of cancer death, are MSS. Delivering a new treatment option to these patients, who do not benefit from today’s immunotherapies, would be transformative. The emerging progression-free survival (PFS) benefit we reported in April is highly encouraging, especially in this tough to treat patient population. We have waited for these clinical data to mature and look forward to sharing the updated dataset next month. If we continue to see evidence of a clinical benefit with GRANITE, as measured by PFS, we believe new hope can be brought to patients who have not been helped by immune checkpoint blockade.”

Dr. Allen added, "Along with advancing GRANITE in CRC, our team continues to innovate across our programs, reinforcing the potential of our underlying technologies. Our recent AACR presentation highlights the unique power of EDGE™, our proprietary neoantigen identification platform that underpins all our programs. Our recent presentation at ESCMID showcases the ability of our self-amplifying mRNA vector (samRNA) to induce long-lasting immune responses. Gritstone remains uniquely positioned to deliver on the promise of next-generation vaccine technologies to prevent, treat and eradicate disease.”

Corporate Updates

In April 2024, Gritstone completed an underwritten public offering resulting in gross proceeds of $32.5 million.

In April 2024, Gritstone appointed Stephen Webster to its Board of Directors. A veteran finance executive with over 30 years in the biotechnology industry, Mr. Webster has held several key roles and been involved in multiple strategic transactions. Mr. Webster was the Chief Financial Officer of Spark Therapeutics from July 2014 until its acquisition by Roche for $4.3 billion in December 2019.

In July 2024, Gritstone bio engaged the Colorectal Cancer Alliance and the Paltown Development Foundation 501(c)(3), the fiduciary for Colontown.org, as part of its effort to educate and empower patients living with colorectal cancer and their caregivers.

In August 2024, Gritstone bio held a virtual KOL event to discuss the unmet need and potential role of GRANITE in metastatic microsatellite-stable colorectal cancer (MSS-CRC). The event featured J. Randolph Hecht, MD, Professor of Clinical Medicine and Director of the UCLA GI Oncology Program, and Howard Brown, CRC Survivor, Patient and Advocate. Details here .

Clinical Program Updates Tumor-Specific Neoantigen Oncology Programs (GRANITE and SLATE) GRANITE – Personalized neoantigen vaccine program SLATE – “Off-the-shelf” neoantigen vaccine program

Preliminary results (reported April 1, 2024) from the ongoing randomized Phase 2 study suggest GRANITE could drive meaningful clinical benefit in front-line metastatic microsatellite-stable colorectal cancer (MSS-CRC). Gritstone expects to report mature progression-free survival (PFS) data in 3Q 2024.

Preliminary data, while immature, showed a trend of extended PFS in GRANITE-treated vs. control patients.

Hazard ratio of 0.82 (18% relative risk reduction of progression or death with GRANITE vs. control) in the overall population, where clinical data are less mature ([95% CI, 0.34-1.67]; 62% censored)

Hazard ratio of 0.52 (48% relative risk reduction of progression or death with GRANITE vs. control) in a fast-progressor, i.e. ‘high-risk’ group 1 , where clinical data are more mature ([95% CI, 0.15-1.38]; 44% censored). Too few events in the slow-progressor group at this early look to draw any efficacy conclusions. 1 Fast-progressor subgroup defined as baseline ctDNA above the median value (2%) for the control group (ctDNA quantified as mean variant allele frequency [VAF] at time of study randomization).

Long-term circulating tumor DNA (ctDNA) data aligned with PFS trend and favored GRANITE vs. control patients

EDGE™ predicts HLA Class I presentation with >80% accuracy. In April 2024, Gritstone presented an update on the predictive performance of both HLA Class I and HLA Class II presentation at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA. The findings further Gritstone’s belief that EDGE is leading the field in neoantigen prediction.

The clinical trial collaboration with the National Cancer Institute (NCI) to evaluate an autologous mutant KRAS-directed TCR-T cell therapy in combination with SLATE-KRAS, Gritstone’s KRAS-directed “off-the-shelf” vaccine candidate, is ongoing. The study is led by Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at the NCI's Center for Cancer Research and builds into the growing interest in combining tumor-antigen specific cell therapy with matched vaccines.

Infectious Disease Programs CORAL – Next-generation SARS-CoV-2 vaccine program that serves as proof-of-concept for Gritstone’s samRNA platform and novel approach in infectious diseases

Efforts to initiate a head-to-head Phase 2b study of Gritstone’s next-generation COVID-19 vaccine (the CORAL Phase 2b study) per the Biomedical Advanced Research and Development Authority (BARDA) 2 contract continue . Gritstone will provide further updates as it is able.

Follow up data from the Phase 1 CORAL study highlight the durability and potential broad utility of Gritstone’s samRNA COVID-19 vaccine. In April 2024, Gritstone presented 12-month follow up data from the Phase 1 CORAL-CEPI at ESCMID 2024. The results reinforced previous findings showing induction of broad and durable immune responses through 12 months.

HIV – Collaboration with Gilead to research and develop vaccine-based HIV immunotherapy treatment

The collaboration with Gilead to research and develop a vaccine-based HIV immunotherapy treatment continues under Gilead’s direction.

Second Quarter 2024 Financial Results

Cash, cash equivalents, marketable securities and restricted cash were $61.7 million as of June 30, 2024, compared to $52.8 million as of March 31, 2024.

Research and development expenses were $20.8 million for the three months ended June 30, 2024, compared to $31.0 million for the three months ended June 30, 2023. The decrease of $10.2 million for the three months ended June 30, 2024, compared to the three months ended June 30, 2023 was primarily due to decreases of $3.2 million in personnel-related expenses, $3.2 million in laboratory supplies, $2.6 million in outside services, consisting primarily of clinical trial and other chemistry, manufacturing and controls related expenses and $1.2 million in facilities related costs.

General and administrative expenses were $7.7 million for the three months ended June 30, 2024, compared to $6.7 million for the three months ended June 30, 2023. The increase of $1.0 million was primarily attributable to increases of $0.9 million in personnel-related expenses, including a $0.5 million increase of non-cash stock-based compensation, and $0.1 million in facilities related costs.

Grant revenues were $0.9 million for the three months ended June 30, 2024. During the three months ended June 30, 2024, we recorded $0.9 million in grant revenue from CEPI.

About Gritstone bio Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets. Independently and with our collaborators, we are advancing a portfolio of product candidates to treat and prevent viral diseases and solid tumors in pursuit of improving patient outcomes and eliminating disease. www.gritstonebio.com

Gritstone Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements related to our clinical and regulatory development plans for our product candidates; our expectations regarding the data to be derived in our ongoing and planned clinical trials; the timing of commencement of our future nonclinical studies, clinical trials and research and development programs; our ability to discover, develop and advance product candidates into, and successfully complete, clinical trials; and our plans and strategy regarding maintaining existing and entering into new collaborations and/or partnerships. Such forward-looking statements involve substantial risks and uncertainties that could cause Gritstone’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including Gritstone’s programs’ clinical stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Gritstone’s ability to successfully establish, protect and defend its intellectual property and other matters that could affect the sufficiency of existing cash to fund operations. Gritstone undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Gritstone’s most recent Annual Report on Form 10-K filed on March 5, 2024 and any subsequent current and periodic reports filed with the Securities and Exchange Commission.

This press release concerns drugs that are under clinical investigation, and which have not yet been approved for marketing by the U.S. Food and Drug Administration. They are currently limited by Federal law to investigational use, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated.

Gritstone Contacts Investors: George E. MacDougall Gritstone bio, Inc. [email protected]

Media: Dan Budwick 1AB (973) 271-6085 [email protected]

Gritstone bio, Inc. Condensed Consolidated Balance Sheets (unaudited) (In thousands)

Gritstone bio, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) (In thousands, except share and per share amounts)

Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

ACIP Presentation Slides: February 22-24, 2023 Meeting

Mpox vaccine, respiratory disease surge, fall 2022, united states, influenza vaccine, pneumococcal vaccines, meningococcal vaccines, polio vaccine.

• RSV Vaccines - Pediatric/Maternal
• RSV Vaccines - Adult

Chikungunya Vaccine

Dengue vaccines, covid-19 vaccines.

Note: These files are not yet 508

Slides will be added as they become available.

February 22, 2023

Welcome & introductions.

• Introduction Dr. G Lee Dr. M Wharton
• Introduction [16 pages] Dr. Pablo Sanchez
• Epidemiology of mpox during 2022 outbreak in the United States [18 pages] Dr. Sascha Ellington
• JYNNEOS Vaccine Safety [26 pages] Dr. Jonathan Duffy
• JYNNEOS Vaccine Effectiveness [21 pages] Dr. Anna Chard
• Mpox vaccine acceptability and uptake from cross-sectional surveys [26 pages] Dr. Kevin P. Delaney
• Interim Clinical Considerations [12 pages] Dr. Rosalind Carter
• EtR: Use of JYNNEOS during mpox outbreaks [48 pages] Dr. Agam Rao
• Dr. José R. Romero
• Introduction [3 pages] Dr. Keipp Talbot
• U.S. Influenza activity update [7 pages] Dr. Lisa Grohskopf
• Preliminary 2022-23 influenza vaccine effectiveness: CDC networks [25 pages] Ms. Samantha Olson, Dr. Nathaniel Lewis, Dr. Mark Tenforde
• Preliminary 2022-23 influenza vaccine effectiveness: Wisconsin [15 pages] Dr. Huong McClean
• Published Estimates of LAIV Effectiveness [4 pages] Dr. Lisa Grohskopf
• Introduction [9 pages] Dr. Katherine Poehling
• Epidemiology of pneumococcal disease among U.S. children [21 pages] Mr. Ryan Gierke
• Estimating the impact of higher-valency PCVs on pediatric outpatient ARI visits and antibiotic use [27 pages] Ms. Laura King
• PCV20 Phase 2/3 study results among children [18 pages] Dr. Wendy Watson
• Preliminary EtR (incl. GRADE) for PCV20 use in U.S. children [57 pages] Dr. Miwako Kobayashi
• Workgroup considerations [12 pages] Dr. Miwako Kobayashi

February 23, 2023

Agency updates.

• Introduction [8 pages] Dr. Kathy Poehling
• Epidemiology of meningococcal disease in the United States [17 pages] Ms. Amy Rubis
• Pfizer pentavalent meningococcal vaccine [26 pages] Dr. Jason Maguire
• Workgroup considerations [15 pages] Dr. Sam Crowe
• Introduction [2 pages] Dr. Oliver Brooks
• Recommendations for Adult Polio Vaccination [29 pages] Dr. Sarah Kidd

RSV Vaccines – Pediatric/Maternal

• Introduction [5 pages] Dr. S Long
• Cost effectiveness analysis for nirsevimab – CDC model [51 pages] Dr. David Hutton
• Cost effectiveness analysis for nirsevimab – Comparison to manufacturer model [25 pages] Dr. Ismael Ortega Sanchez
• Evidence to Recommendations framework for nirsevimab [92 pages] Dr. Jefferson Jones
• Clinical considerations for nirsevimab [16 pages] Dr. Jefferson Jones
• Safety and Efficacy of RSV Bivalent PreF Maternal Vaccine [31 pages] Dr. Iona Munjal
• Workgroup considerations [6 pages] Dr. Katherine Fleming-Dutra

RSV Vaccines – Adult

• Introduction [8 pages] Dr. Camille Kotton
• Cost effectiveness of the GSK and Pfizer vaccines (main CDC model) [37 pages] Dr. David Hutton
• Comparison of cost effectiveness results of the main CDC model and each manufacturer model (GSK & Pfizer) [24 pages] Dr. Ismael Ortega Sanchez
• EtR (incl. GRADE) for 2 vaccines (GSK & Pfizer) [90 pages] Dr. Michael Melgar
• Vaccine policy questions (GSK & Pfizer) [2 pages] Dr. Michael Melgar
• Introduction [7 pages] Dr. Beth Bell
• Global epidemiology of chikungunya [12 pages] Dr. Susan Hills
• Chikungunya in U.S. travelers [15 pages] Ms. Nicole Lindsey
• Persistent arthralgia following chikungunya [21 pages] Ms. Nicole Lindsey
• Workgroup considerations [4 pages] Ms. Nicole Lindsey
• Introduction [8 pages] Dr. W Chen
• Takeda dengue vaccine (TAK-003) safety and efficacy [26 pages] Dr. Shibidas Biswal
• Workgroup considerations [22 pages] Dr. Gabriela Paz-Bailey
• Public health impact of 25 years of varicella vaccination in the United States [23 pages] Dr. Mona Marin

February 24, 2023

• Introduction [7 pages] Dr. Matthew Daley
• COVID-19 vaccine safety updates: CDC [43 pages] Dr. Tom Shimabukuro
• COVID-19 vaccine safety updates: FDA [17 pages] Dr. Richard Forshee
• VaST summary [10 pages] Dr. Keipp Talbot
• WG interpretation and summary [19 pages] Dr. Evelyn Twentyman
• Updates on COVID-19 hospitalizations: COVID-NET [14 pages] Dr. Chris Taylor
• Updates to COVID-19 vaccine effectiveness in the United States [29 pages] Dr. Amadea Britton
• Considerations for transitioning to bivalent primary series [32 pages] Dr. Sara Oliver
• Benefit/risk for COVID-19 vaccines [21 pages] Dr. Megan Wallace
• COVID-19 vaccines: future directions [37 pages] Dr. Sara Oliver